Abstract
Radical cystectomy (RC) still represents the gold standard therapy for muscle-invasive urinary bladder cancer (MIBC) with 66% recurrence-free survival at 10 years follow-up.1 In the last decade robot-assisted radical cystectomy (RARC) has been increasingly adopted for the treatment of MIBC, resulting not inferior to open surgery regarding surgical complications and oncological outcomes, whereas the supposed benefits of a mini-invasive approach and less surgical trauma basing on reduced hospital stay and improved postoperative QoL could be not demonstrated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
